IN2014DN03325A - - Google Patents
Info
- Publication number
- IN2014DN03325A IN2014DN03325A IN3325DEN2014A IN2014DN03325A IN 2014DN03325 A IN2014DN03325 A IN 2014DN03325A IN 3325DEN2014 A IN3325DEN2014 A IN 3325DEN2014A IN 2014DN03325 A IN2014DN03325 A IN 2014DN03325A
- Authority
- IN
- India
- Prior art keywords
- compound
- directed
- composition
- sulphur
- selene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161543510P | 2011-10-05 | 2011-10-05 | |
| NL2007536A NL2007536C2 (en) | 2011-10-05 | 2011-10-05 | Adjuvant compound. |
| US201261615566P | 2012-03-26 | 2012-03-26 | |
| PCT/NL2012/050694 WO2013051936A1 (en) | 2011-10-05 | 2012-10-04 | Adjuvant compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN03325A true IN2014DN03325A (ja) | 2015-06-26 |
Family
ID=48043964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3325DEN2014 IN2014DN03325A (ja) | 2011-10-05 | 2012-10-04 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9314521B2 (ja) |
| EP (1) | EP2763697B9 (ja) |
| JP (1) | JP6099210B2 (ja) |
| KR (1) | KR102053699B1 (ja) |
| CN (1) | CN104244976B (ja) |
| AU (1) | AU2012319265B2 (ja) |
| BR (1) | BR112014008214B1 (ja) |
| CA (1) | CA2886631C (ja) |
| EA (1) | EA030741B1 (ja) |
| ES (1) | ES2952644T3 (ja) |
| IL (1) | IL231951B (ja) |
| IN (1) | IN2014DN03325A (ja) |
| MX (1) | MX356028B (ja) |
| NL (1) | NL2007536C2 (ja) |
| SG (1) | SG11201401291XA (ja) |
| WO (1) | WO2013051936A1 (ja) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014234400B2 (en) | 2013-03-21 | 2017-11-16 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| SG11201506885UA (en) | 2013-03-21 | 2015-09-29 | Sanofi Aventis Deutschland | Synthesis of cyclic imide containing peptide products |
| CN109893648A (zh) | 2013-06-28 | 2019-06-18 | 奥克兰联合服务有限公司 | 氨基酸缀合物和肽缀合物及缀合方法 |
| EP3148566B1 (en) | 2014-06-02 | 2024-04-03 | ISA Pharmaceuticals B.V. | Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection |
| WO2016103192A1 (en) | 2014-12-23 | 2016-06-30 | Margaret Anne Brimble | Amino acid and peptide conjugates and uses thereof |
| MY196837A (en) | 2015-12-11 | 2023-05-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201521894D0 (en) * | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| EP3419962A4 (en) | 2016-02-26 | 2020-03-11 | Auckland Uniservices Limited | AMINO ACID AND PEPTIDE CONJUGATES AND CONJUGATION METHOD |
| US10702598B2 (en) | 2016-06-20 | 2020-07-07 | Isa Pharmaceuticals B.V. | Formulation of a peptide vaccine |
| IL263616B1 (en) | 2016-07-07 | 2024-09-01 | Univ Leland Stanford Junior | Antibody-adjuvant conjugates |
| WO2019122050A1 (en) | 2017-12-22 | 2019-06-27 | Isa Pharmaceuticals B.V. | Methods of immunization |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| KR20220143812A (ko) | 2019-12-07 | 2022-10-25 | 아이에스에이 파마슈티컬즈 비.브이. | B형 간염 바이러스와 관련된 질병의 치료 |
| US20230087422A1 (en) | 2020-02-07 | 2023-03-23 | Isa Pharmaceuticals B.V. | Treatment of hpv-related diseases |
| US20230143215A1 (en) | 2020-04-23 | 2023-05-11 | Isa Pharmaceuticals B.V. | Immunization against sars-cov-related diseases |
| EP4370903A1 (en) | 2021-07-12 | 2024-05-22 | ISA Pharmaceuticals B.V. | Improved substance quantification in complex mixtures |
| WO2024068636A1 (en) | 2022-09-27 | 2024-04-04 | Isa Pharmaceuticals B.V. | Adjuvanted immunogenic peptides for intradermal administration |
| WO2024079311A1 (en) | 2022-10-13 | 2024-04-18 | Isa Pharmaceuticals B.V. | Modified long peptides suitable for use in immunisation |
| WO2024149888A1 (en) | 2023-01-12 | 2024-07-18 | Isa Pharmaceuticals B.V. | Improved lipopeptide quantification |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3485094D1 (de) * | 1983-01-25 | 1991-10-31 | Ciba Geigy Ag | Neue peptidderivate. |
| DE3937412A1 (de) * | 1989-11-10 | 1991-05-16 | Hoechst Ag | Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten |
| US6024964A (en) * | 1985-06-24 | 2000-02-15 | Hoechst Aktiengesellschaft | Membrane anchor/active compound conjugate, its preparation and its uses |
| US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| US6686447B1 (en) | 1999-06-30 | 2004-02-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030211510A1 (en) | 1999-06-30 | 2003-11-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6504010B1 (en) | 1999-06-30 | 2003-01-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| MXPA02000192A (es) | 1999-06-30 | 2004-08-12 | Corixa Corp | Composiciones y metodos para la terapia y diagnostico de cancer de pulmon. |
| NL1012739C2 (nl) | 1999-07-29 | 2001-01-30 | Maasland Nv | Voerinrichting, in het bijzonder voor het verstrekken van krachtvoer. |
| CA2431500C (en) | 2000-12-08 | 2016-06-07 | Sjoerd Hendrikus Van Der Burg | Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses |
| MXNL04000056A (es) | 2004-06-30 | 2006-01-11 | Mario Alberto Aguilera Rico | Sistema de construccion terra acero. |
| JP2010500407A (ja) * | 2006-08-14 | 2010-01-07 | サイモン・エル・エル・シー | Ｈｉｖ−１の複数の株及びサブタイプを治療及び予防するための組成物及び方法 |
| CA2996732C (en) | 2007-03-26 | 2020-10-27 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Prame derived peptides and immunogenic compositions comprising these |
| AU2008257791B2 (en) | 2007-05-31 | 2013-03-28 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | P53 peptide vaccine |
| CA2692652C (en) | 2007-05-31 | 2018-10-23 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines |
| KR100900837B1 (ko) * | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물 |
| CN102905703B (zh) * | 2010-03-23 | 2016-09-28 | 诺华股份有限公司 | 作为tlr2激动剂用于治疗感染、炎症、呼吸疾病等的化合物(基于半胱氨酸的脂肽)和组合物 |
-
2011
- 2011-10-05 NL NL2007536A patent/NL2007536C2/en active
-
2012
- 2012-10-04 WO PCT/NL2012/050694 patent/WO2013051936A1/en active Application Filing
- 2012-10-04 EP EP12780309.6A patent/EP2763697B9/en active Active
- 2012-10-04 JP JP2014534504A patent/JP6099210B2/ja active Active
- 2012-10-04 CN CN201280059738.4A patent/CN104244976B/zh active Active
- 2012-10-04 CA CA2886631A patent/CA2886631C/en active Active
- 2012-10-04 KR KR1020147012025A patent/KR102053699B1/ko active IP Right Grant
- 2012-10-04 BR BR112014008214-6A patent/BR112014008214B1/pt active IP Right Grant
- 2012-10-04 SG SG11201401291XA patent/SG11201401291XA/en unknown
- 2012-10-04 MX MX2014004114A patent/MX356028B/es active IP Right Grant
- 2012-10-04 IN IN3325DEN2014 patent/IN2014DN03325A/en unknown
- 2012-10-04 ES ES12780309T patent/ES2952644T3/es active Active
- 2012-10-04 EA EA201490709A patent/EA030741B1/ru not_active IP Right Cessation
- 2012-10-04 AU AU2012319265A patent/AU2012319265B2/en active Active
- 2012-10-04 US US14/349,652 patent/US9314521B2/en active Active
-
2014
- 2014-04-03 IL IL231951A patent/IL231951B/en active IP Right Grant
-
2016
- 2016-03-07 US US15/062,589 patent/US9770506B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX356028B (es) | 2018-05-09 |
| JP2014530808A (ja) | 2014-11-20 |
| CA2886631C (en) | 2019-06-11 |
| US9314521B2 (en) | 2016-04-19 |
| BR112014008214A2 (pt) | 2017-06-13 |
| SG11201401291XA (en) | 2014-05-29 |
| EP2763697B8 (en) | 2023-07-12 |
| KR102053699B1 (ko) | 2019-12-09 |
| US9770506B2 (en) | 2017-09-26 |
| NZ623869A (en) | 2015-11-27 |
| US20160250325A1 (en) | 2016-09-01 |
| AU2012319265A1 (en) | 2014-05-22 |
| EA201490709A1 (ru) | 2014-09-30 |
| CA2886631A1 (en) | 2013-04-11 |
| IL231951B (en) | 2019-08-29 |
| CN104244976A (zh) | 2014-12-24 |
| BR112014008214B1 (pt) | 2022-07-05 |
| CN104244976B (zh) | 2017-05-31 |
| EP2763697A1 (en) | 2014-08-13 |
| ES2952644T3 (es) | 2023-11-02 |
| KR20140093673A (ko) | 2014-07-28 |
| EP2763697C0 (en) | 2023-06-07 |
| WO2013051936A1 (en) | 2013-04-11 |
| EP2763697B1 (en) | 2023-06-07 |
| EA030741B1 (ru) | 2018-09-28 |
| MX2014004114A (es) | 2014-10-17 |
| JP6099210B2 (ja) | 2017-03-22 |
| IL231951A0 (en) | 2014-05-28 |
| EP2763697B9 (en) | 2023-10-04 |
| NL2007536C2 (en) | 2013-04-08 |
| US20150104473A1 (en) | 2015-04-16 |
| AU2012319265B2 (en) | 2016-10-13 |
| WO2013051936A9 (en) | 2013-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN03325A (ja) | ||
| WO2016077464A8 (en) | Amino acid derivatives and their uses | |
| BR112012007411A2 (pt) | composto, processo para sua preparação e composição farmacêutica contendo o mesmo | |
| TR201900128T4 (tr) | Amino asit 1'de ve 3'te modifiye edilmiş siklosporin analoğu moleküller. | |
| MX2010007587A (es) | Compuestos que comprenden un grupo ciclobutoxi. | |
| MY159252A (en) | Process for the preparation of dopo-derived compounds and compositions thereof | |
| BR112013020996A8 (pt) | derivados aminobutíricos substituídos como inibidores de neprilisina | |
| MX2012002502A (es) | Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos. | |
| MY150596A (en) | Hsp90 inhibitors | |
| MY156938A (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
| WO2012080284A3 (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | |
| JO2910B1 (en) | Organic compounds | |
| MX2011007952A (es) | Tricianoboratos novedosos. | |
| BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
| MX2013000295A (es) | Procedimiento de preparacion de un inhibidor especifico de la trombina. | |
| MX352607B (es) | Proceso para la preparacion de benzoxaboroles. | |
| MY167638A (en) | Treatment composition for textile goods | |
| WO2009137444A3 (en) | Cure accelerators for anaerobic curable compositions | |
| NZ704155A (en) | Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof | |
| BR112012009311A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
| BR112012009861A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| MY164880A (en) | Process for the preparation of isoxazolyl-methoxy-nicotinic acids | |
| BR112013024361A2 (pt) | novos compostos de azaspirodecanona como inibidores de hsl | |
| MX2013003387A (es) | Proceso para preparacion de producto de reaccion de urea ciclica y de aldehido multifuncional. | |
| EA201390170A1 (ru) | Составы |